- A tiny wireless implant placed under the retina helped many people with advanced age related macular degeneration regain useful central vision in a clinical trial.
- After one year, most participants improved on standard eye chart testing and many reported using the device at home to read letters, numbers, and in some cases words.
- The system works with special glasses that send visual information to the implant using near infrared light, which is then converted into electrical signals to stimulate surviving retinal cells.
A miniature retinal implant has produced some of the strongest results yet seen in attempts to restore central vision for people with advanced age related macular degeneration, a leading cause of permanent vision loss in older adults.
The findings, published in the New England Journal of Medicine, come from an international clinical trial involving people with advanced atrophic macular degeneration, also known as geographic atrophy.
Geographic atrophy damages the retina’s light sensing cells in the central part of vision.
In a healthy eye, these photoreceptors convert light into electrical signals that pass through retinal nerve cells and along the optic nerve to the brain. When those photoreceptors are lost, central vision becomes blurred or absent, making tasks like reading and recognising faces very difficult.
The device tested in this study is designed to bypass the damaged photoreceptors.
It is a tiny wireless implant, about 2 by 2 millimetres, placed under the retina. Participants wear specialised glasses with a built in camera.
The camera captures the scene and the glasses project the information to the implant using near infrared light that is not visible to the human eye.
The implant converts that light into electrical pulses that stimulate remaining retinal cells, helping visual signals reach the brain again. Users can adjust settings such as zoom and contrast to improve clarity.
In the trial, 38 participants aged 60 years and over were enrolled across 17 medical centres in France, Germany, Italy, the Netherlands, and the United Kingdom.
Among the 32 people who completed a full year of follow up, 26 showed meaningful improvement in visual acuity testing.
On average, participants gained around 25 letters on a standard eye chart when using the implant, which is roughly five lines.
Most participants also reported using the artificial vision at home, with many able to identify letters and some able to read words. One participant improved by 59 letters, which is about 12 lines on the chart.
Safety also mattered. The researchers reported that side effects linked to the procedure had resolved by 12 months.
- Dry eye disease: tear glands may explain why millions struggle with irritated eyes
- Robbie Williams believes eyesight worries are linked to weight loss injections
The results do not mean the implant restores perfect vision, but they do suggest a meaningful shift for people who previously had very limited central vision.
The manufacturer, Science Corporation, has submitted applications seeking approval for clinical use in Europe and the United States. Research is continuing to explore whether outcomes can be improved further and how the technology might evolve.
For a diabetes audience, it is worth noting that this implant is aimed at macular degeneration rather than diabetic eye disease.
Even so, progress in retinal technology is moving quickly, and developments like this are relevant because many people living with diabetes are also managing age related eye conditions as they get older.
If you have diabetes and notice changes in vision, the practical takeaway remains the same: report symptoms promptly and keep up with regular eye checks, as early assessment is still the best protection against avoidable vision loss.
